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Nociceptin (NOC) and Nocistatin (NS) are two neu-
ropeptides derived from pre-pro-nociceptin. NOC is the
endogenous ligand of the NOP receptor which exhibits
marked structural analogy with opioid receptors. NOC
has been reported to exert multiple effects in the gastroin-
testinal tract. The aims of this study were to compare the
gastroprotective effects of NOC and NS and to analyse the
mechanism of their gastroprotective action. Gastric
mucosal damage was induced by acidified ethanol in rats.
The compounds were given i.c.v. Both NOC and NS (0.2–
5 nmol/rat) induced gastroprotective effects. Pre-adminis-
tration of NS significantly decreased the effect of NOC, as
well as the competitive antagonist J-113397 (70 nmol/
rat) and vagotomy. The effect of both neuropeptides was
reduced by naloxone (27 nmol/rat), naltrindole (4.8
nmol/rat), norbinaltorphimine (10 μg/rat) and β-FNA
(20 nmol/rat). In conclusion, both NOC and NS initiate
centrally a series of events which result in gastric mucosal
defense. The gastroprotective effect of NOC and NS is
likely to be mediated by endogenous opioids and con-
veyed to the periphery by a vagal-dependent mechanism.
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